Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023
Recommended Citation
Chung JR, Shirk P, Gaglani M, Mutnal MB, Nowalk MP, Moehling Geffel K, House SL, Curley T, Wernli KJ, Kiniry EL, Martin ET, Vaughn IA, Murugan V, Lim ES, Saade E, Faryar K, Williams OL, Walter EB, Price AM, Barnes JR, DaSilva J, Kondor R, Ellington S, and Flannery B. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses 2024; 18(6):e13342.
Document Type
Article
Publication Date
6-1-2024
Publication Title
Influenza Other Respir Viruses
Abstract
BACKGROUND: The 2022-23 US influenza season peaked early in fall 2022.
METHODS: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design.
RESULTS: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval -9%, 54%); low late-season activity precluded estimation for most subgroups.
CONCLUSIONS: 2022-23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.
Medical Subject Headings
Humans; Influenza Vaccines; Influenza, Human; Adult; Male; Female; United States; Middle Aged; Young Adult; Adolescent; Aged; Child; Influenza A Virus, H3N2 Subtype; Child, Preschool; Influenza A Virus, H1N1 Subtype; Outpatients; Seasons; Vaccine Efficacy; Infant; Vaccination; Aged, 80 and over
PubMed ID
38923314
Volume
18
Issue
6
First Page
13342
Last Page
13342
